Trials / Completed
CompletedNCT01845311
ReZolve2 Clinical Investigation
RESTORE II Trial: Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- REVA Medical, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2 Bioresorbable Coronary Scaffold in native coronary arteries.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ReZolve2 Scaffold |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2014-01-01
- Completion
- 2019-01-01
- First posted
- 2013-05-03
- Last updated
- 2023-03-29
Locations
3 sites across 3 countries: Australia, Brazil, Germany
Source: ClinicalTrials.gov record NCT01845311. Inclusion in this directory is not an endorsement.